Clinical Trials Browser

derazantinib × Clear all

NCT05174650 2025-12-05

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT04087876 2025-04-06

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

No longer available

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT04604132 2024-04-04

FIDES-03

Phase 1/2 Terminated

47 enrolled 22 charts

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT03230318 2023-12-19

FIDES-01

Phase 2 Completed

148 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT04045613 2023-10-13

FIDES-02

Phase 1/2 Completed

95 enrolled 25 charts

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01752920 2023-06-05

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Phase 1/2 Completed

119 enrolled 15 charts

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Neoplasms, Cholangiocarcinoma